LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Kodu・Aktsiate loetelu・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Suletud

SektorTervishoid

8.84 -14.34

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

8.67

Max

9.99

Põhinäitajad
By Trading Economics
Sissetulek	11M -20M
Müük	5.9M 40M
Aktsiakasum	-0.19
Kasumimarginaal	-49.569
Töötajad	184
EBITDA	16M -19M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+138.59% upside

Turustatistika
By TradingEconomics
Turukapital	294M 1B
Eelmine avamishind	23.18
Eelmine sulgemishind	8.84

Uudiste sentiment

By Acuity

50%

171 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

6.26 / 7.47 Toetus ja vastupanu

Day One Biopharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. nov 2025, 21:34 UTC

Tulu

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13. nov 2025, 23:45 UTC

Market Talk

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13. nov 2025, 23:42 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13. nov 2025, 23:41 UTC

Market Talk

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13. nov 2025, 23:24 UTC

Tulu

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q EPS 52c >JBS

13. nov 2025, 23:23 UTC

Tulu

JBS NV 3Q Sales $22.6B >JBS

13. nov 2025, 23:04 UTC

Market Talk

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13. nov 2025, 22:02 UTC

Tulu

Nu Holdings 3Q Net $783M >NU

13. nov 2025, 22:01 UTC

Tulu

Nu Holdings 3Q Rev $4.2B >NU

13. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13. nov 2025, 21:50 UTC

Tulu

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13. nov 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13. nov 2025, 21:41 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13. nov 2025, 21:36 UTC

Omandamised, ülevõtmised, äriostud

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13. nov 2025, 21:33 UTC

Market Talk

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13. nov 2025, 21:33 UTC

Tulu

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13. nov 2025, 21:31 UTC

Tulu

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13. nov 2025, 21:25 UTC

Tulu

Figure Tech Solutions 3Q EPS 34c >FIGR

13. nov 2025, 21:23 UTC

Tulu

Intchains Group 3Q Rev $1.3M >ICG

13. nov 2025, 21:03 UTC

Tulu

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13. nov 2025, 21:02 UTC

Tulu

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Rev $6.8B >AMAT

13. nov 2025, 21:01 UTC

Tulu

Applied Materials 4Q Gross Margin 48.0% >AMAT

Võrdlus sarnastega

Hinnamuutus

Day One Biopharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

138.59% tõus

12 kuu keskmine prognoos

Keskmine 24.67 USD 138.59%

Kõrge 34 USD

Madal 16 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Day One Biopharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

Osta

Hoia

Müü

Põhineb 8 analüütiku instrumendi Day One Biopharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

6.26 / 7.47Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentiment

By Acuity

171 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.